bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Table 4 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Authors: Wainberg Zev A. , Singh Arun S. , Konecny Gottfried E. , McCann Kelly E. , Hecht J. Randolph , Goldman Jonathan , Chmielowski Bartosz , Finn Richard S. , O'Brien Neil , Von Euw Erika , Price Megan M. , Martinez Diego , Yonemoto Lisa , Brennan Meghan , Glaspy John A. , Slamon Dennis J.
Published: April 2023

Supplemental Table 4
Supplementary Table from Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Authors: Yin Yanping , Athanasiadis Paschalis , Karlsen Linda , Urban Aleksandra , Xu Haifeng , Murali Ishwarya , Fernandes Stacey M. , Arribas Alberto J. , Hilli Abdul K. , Taskén Kjetil , Bertoni Francesco , Mato Anthony R. , Normant Emmanuel , Brown Jennifer R. , Tjønnfjord Geir E. , Aittokallio Tero , Skånland Sigrid S.
Published: April 2023

Supplementary Table from Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Supplementary Tables S1-S6 from Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Authors: Canali Alban , Vergnolle Inès , Bertoli Sarah , Largeaud Laetitia , Nicolau Marie-Laure , Rieu Jean-Baptiste , Tavitian Suzanne , Huguet Françoise , Picard Muriel , Bories Pierre , Vial Jean Philippe , Lechevalier Nicolas , Béné Marie Christine , Luquet Isabelle , Mansat-De Mas Véronique , Delabesse Eric , Récher Christian , Vergez François
Published: April 2023

Supplemental Table 1. Characteristics of AML patients.
Supplemental Table 2. Flow cytometry antibodies.
Supplemental Table 3. Multivariate Cox regression analysis of factors contributing to overall survival
of AML patients.
Supplemental Table 4. Multivariate Cox regression analysis of factors contributing to leukemia free
survival of AML patients.
Supplemental Table 5. Multivariate Cox regression analysis of factors contributing to overall survival
of AML patients including the association of bulk and LSC MRD parameters.
Supplemental Table 6. Multivariate Cox regression analysis of factors contributing to leukemia free
survival of AML patients including the association of bulk and LSC MRD parameters.
Table S1 from Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
Authors: Wang Zhi-ming , Zhuang Rong-yuan , Guo Xi , Zhang Chen-lu , You Yang , Chen Li-sha , Liu Wen-shuai , Zhang Yong , Luo Rong-kui , Hou Ying-yong , Lu Wei-qi , Zhou Yu-hong
Published: April 2023

Representativeness of Study Participants
Supplementary Data from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
Authors: Mao Lili , Fang Meiyu , Chen Yu , Wei Xiaoting , Cao Jun , Lin Jing , Zhang Peng , Chen Ling , Cao Xiao , Chen Yujun , Guo Jun , Si Lu
Published: April 2023

Supplementary Data from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
Supplementary Figure S5 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
Authors: Paudel Sarita , Warner Benjamin E. , Wang Renwei , Adams-Haduch Jennifer , Reznik Alex S. , Dou Jason , Huang Yufei , Gao Yu-Tang , Koh Woon-Puay , Bäckerholm Alan , Yuan Jian-Min , Shair Kathy H.Y.
Published: April 2023

Serum IgA detection of viral antigens from reactivated HH514-16 lysates.
Sera from 38 SCHS and SCS validation pairs (0<10 years to diagnosis and EBNA1 IgA false-positives) were used to probe cell lysates prepared by sodium butyrate reactivation of HH514-16 cells. (A) Example of immunoblot detection of induced (I) and uninduced (U) HH514-16 lysates by sera from NPC case-control pairs within 3 years to diagnosis (NPC45, C45) and >3 years (NPC30, C30) with band calls shown as red dots. Estimated molecular weight (MW) in kilodaltons (kDa) and protein band locations of several early EBV proteins are shown (EA p138 (BALF2), EBNA1 (BKRF1), TK (BXLF1), DNase (BGLF5), EA-D (BMRF1), VCA p40 (BdRF1), ZEBRA (BZLF1), VCA p18 (BFRF3)) (13). EA-D can be multiple bands ranging 47-54 kDa. (B) The number of protein bands detected (band count) are shown for cases (black triangle) and controls (grey inverted triangle) which are grouped by number of years to NPC case diagnosis (years to NPC dx). NPC cases within 2 years to diagnosis (blue triangle) and controls that tested positive for EBNA1 IgA (filled grey inverted triangle). are identified. Median=red bar, n=number of sera in each group. Statistical significance is labeled as *p<0.05, **p<0.001, calculated by a Mann-Whitney test.
Supplementary File 1 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
Authors: Ge Huaibin , Ferris Robert L. , Wang Jing H.
Published: April 2023

Supplementary File 1
Supplementary Figure S1 from Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma
Authors: Paudel Sarita , Warner Benjamin E. , Wang Renwei , Adams-Haduch Jennifer , Reznik Alex S. , Dou Jason , Huang Yufei , Gao Yu-Tang , Koh Woon-Puay , Bäckerholm Alan , Yuan Jian-Min , Shair Kathy H.Y.
Published: April 2023

Detection of EBV-specific IgG in sera from incident NPC cases and healthy controls in the SCHS cohort.
Heatmap depicting IgG heavy chain-specific (IgGH) normalized detection values from 20 incident NPC case-control pairs. The data is represented similarly to Fig 2 with Fisher’s exact test identifying proteins (bolded) that discriminate case from controls and denoted *p<0.05, **p<0.01, ***p<0.001.
Supplementary Table from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
Authors: Benhamouda Nadine , Sam Ikuan , Epaillard Nicolas , Gey Alain , Phan Letuan , Pham Hang Phuong , Gruel Nadège , Saldmann Antonin , Pineau Joséphine , Hasan Milena , Quiniou Valentin , Nevoret Camille , Verkarre Virginie , Libri Valentina , Mella Sebastien , Granier Clémence , Broudin Chloe , Ravel Patrice , De Guillebon Eléonore , Mauge Laetitia , Helley Dominique , Jabla Bernd , Chaput Nathalie , Albiges Laurence , Katsahian Sandrine , Adam Julien , Mejean Arnaud , Adotevi Olivier , Vano Yann A. , Oudard Stéphane , Tartour Eric
Published: April 2023

Supplementary Table from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
Supplementary Data from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
Authors: Benhamouda Nadine , Sam Ikuan , Epaillard Nicolas , Gey Alain , Phan Letuan , Pham Hang Phuong , Gruel Nadège , Saldmann Antonin , Pineau Joséphine , Hasan Milena , Quiniou Valentin , Nevoret Camille , Verkarre Virginie , Libri Valentina , Mella Sebastien , Granier Clémence , Broudin Chloe , Ravel Patrice , De Guillebon Eléonore , Mauge Laetitia , Helley Dominique , Jabla Bernd , Chaput Nathalie , Albiges Laurence , Katsahian Sandrine , Adam Julien , Mejean Arnaud , Adotevi Olivier , Vano Yann A. , Oudard Stéphane , Tartour Eric
Published: April 2023

Supplementary Data from Plasma CD27, a Surrogate of the Intratumoral CD27–CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma
Supplementary fig 1 from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412
Authors: Davis Kara L. , Fox Elizabeth , Isikwei Emasenyie , Reid Joel M. , Liu Xiaowei , Minard Charles G. , Voss Stephan , Berg Stacey L. , Weigel Brenda J. , Mackall Crystal L.
Published: April 2023

Supplementary Figure 1. Nivolumab (A) and Ipilumumab (B) peak and trough concentrations in treatment cycles 1 – 4.
Supplementary Figures1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas
Authors: Jungwirth Gerhard , Yu Tao , Liu Fang , Cao Junguo , Alaa Eddine Montadar , Moustafa Mahmoud , Abdollahi Amir , Warta Rolf , Unterberg Andreas , Herold-Mende Christel
Published: April 2023

Supplementary Figures
Supplementary Figure from Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Authors: Pollyea Daniel A. , Pratz Keith W. , Wei Andrew H. , Pullarkat Vinod , Jonas Brian A. , Recher Christian , Babu Sunil , Schuh Andre C. , Dail Monique , Sun Yan , Potluri Jalaja , Chyla Brenda , DiNardo Courtney D.
Published: April 2023

Supplementary Figure from Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Supplementary Figure from Osimertinib plus Selumetinib in EGFR-Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)
Authors: Yang James Chih-Hsin , Ohe Yuichiro , Chiu Chao-Hua , Ou Xiaoling , Cantarini Mireille , Jänne Pasi A. , Hartmaier Ryan J. , Ahn Myung Ju
Published: April 2023

Supplementary Figure from Osimertinib plus Selumetinib in EGFR-Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)
Supplementary Data from Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer
Authors: Pietzak Eugene J. , Whiting Karissa , Srinivasan Preethi , Bandlamudi Chaitanya , Khurram Aliya , Joseph Vijai , Walasek Aleksandra , Bochner Emily , Clinton Timothy , Almassi Nima , Truong Hong , de Jesus Escano Manuel R. , Wiseman Michal , Mandelker Diana , Kemel Yelena , Zhang Liying , Walsh Michael F. , Cadoo Karen A. , Coleman Jonathan A. , Al-Ahmadie Hikmat , Rosenberg Jonathan E. , Iyer Gopakumar V. , Solit David B. , Ostrovnaya Irina , Offit Kenneth , Robson Mark E. , Stadler Zsofia K. , Berger Michael F. , Bajorin Dean F. , Carlo Maria , Bochner Bernard H.
Published: April 2023

Supplementary Data from Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer
Supplementary Table S2 from Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
Authors: Peng Ke , Zhang Feifei , Wang Yichen , Sahgal Pranshu , Li Tianxia , Zhou Jin , Liang Xiaoyan , Zhang Yanxi , Sethi Nilay , Liu Tianshu , Zhang Haisheng , Bass Adam J.
Published: April 2023

Drug List
Figure S6 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Authors: Kang Kyung-Don , Bernstock Joshua D. , Totsch Stacie K. , Gary Sam E. , Rocco Abbey , Nan Li , Li Rong , Etminan Tina , Han Xiaosi , Beierle Elizabeth A. , Eisemann Tanja , Wechsler-Reya Robert J. , Bae Sejong , Whitley Richard , Gillespie G. Yancey , Markert James M. , Friedman Gregory K.
Published: April 2023

Time to recover baseline body weight in mice pretreated with low-dose oHSV prior to a standard treatment dose.
Figure S1 from Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers
Authors: Kang Kyung-Don , Bernstock Joshua D. , Totsch Stacie K. , Gary Sam E. , Rocco Abbey , Nan Li , Li Rong , Etminan Tina , Han Xiaosi , Beierle Elizabeth A. , Eisemann Tanja , Wechsler-Reya Robert J. , Bae Sejong , Whitley Richard , Gillespie G. Yancey , Markert James M. , Friedman Gregory K.
Published: April 2023

Body weights of CBA/J, BALB/c and C57BL/6 mice (N = 5/group) after inoculation with 1x107 PFU of IVT oHSV.
Supplementary Figure from Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant
Authors: Wimberger Pauline , Gerber Mara Julia , Pfisterer Jacobus , Erdmann Kati , Füssel Susanne , Link Theresa , du Bois Andreas , Kommoss Stefan , Heitz Florian , Sehouli Jalid , Kimmig Rainer , de Gregorio Nikolaus , Schmalfeldt Barbara , Park-Simon Tjoung-Won , Baumann Klaus , Hilpert Felix , Grube Marcel , Schröder Willibald , Burges Alexander , Belau Antje , Hanker Lars , Kuhlmann Jan Dominik
Published: April 2023

Supplementary Figure from Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant
Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Authors: Meagher Nicola S. , Gorringe Kylie L. , Wakefield Matthew , Bolithon Adelyn , Pang Chi Nam Ignatius , Chiu Derek S. , Anglesio Michael S. , Mallitt Kylie-Ann , Doherty Jennifer A. , Harris Holly R. , Schildkraut Joellen M. , Berchuck Andrew , Cushing-Haugen Kara L. , Chezar Ksenia , Chou Angela , Tan Adeline , Alsop Jennifer , Barlow Ellen , Beckmann Matthias W. , Boros Jessica , Bowtell David D.L. , Brand Alison H. , Brenton James D. , Campbell Ian , Cheasley Dane , Cohen Joshua , Cybulski Cezary , Elishaev Esther , Erber Ramona , Farrell Rhonda , Fischer Anna , Fu Zhuxuan , Gilks Blake , Gill Anthony J. , Gourley Charlie , Grube Marcel , Harnett Paul R. , Hartmann Arndt , Hettiaratchi Anusha , Høgdall Claus K. , Huzarski Tomasz , Jakubowska Anna , Jimenez-Linan Mercedes , Kennedy Catherine J. , Kim Byoung-Gie , Kim Jae-Weon , Kim Jae-Hoon , Klett Kayla , Koziak Jennifer M. , Lai Tiffany , Laslavic Angela , Lester Jenny , Leung Yee , Li Na , Liauw Winston , Lim Belle W.X. , Linder Anna , Lubiński Jan , Mahale Sakshi , Mateoiu Constantina , McInerny Simone , Menkiszak Janusz , Minoo Parham , Mittelstadt Suzana , Morris David , Orsulic Sandra , Park Sang-Yoon , Pearce Celeste Leigh , Pearson John V. , Pike Malcolm C. , Quinn Carmel M. , Mohan Ganendra Raj , Rao Jianyu , Riggan Marjorie J. , Ruebner Matthias , Salfinger Stuart , Scott Clare L. , Shah Mitul , Steed Helen , Stewart Colin J.R. , Subramanian Deepak , Sung Soseul , Tang Katrina , Timpson Paul , Ward Robyn L. , Wiedenhoefer Rebekka , Thorne Heather , Cohen Paul A. , Crowe Philip , Fasching Peter A. , Gronwald Jacek , Hawkins Nicholas J. , Høgdall Estrid , Huntsman David G. , James Paul A. , Karlan Beth Y. , Kelemen Linda E. , Kommoss Stefan , Konecny Gottfried E. , Modugno Francesmary , Park Sue K. , Staebler Annette , Sundfeldt Karin , Wu Anna H. , Talhouk Aline , Pharoah Paul D.P. , Anderson Lyndal , DeFazio Anna , Köbel Martin , Friedlander Michael L. , Ramus Susan J.
Published: April 2023

Supplementary Tables S1-S11
Supplementary Data S1-S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Authors: Asleh Karama , Lluch Ana , Goytain Angela , Barrios Carlos , Wang Xue Q. , Torrecillas Laura , Gao Dongxia , Ruiz-Borrego Manuel , Leung Samuel , Bines José , Guerrero-Zotano Ángel , García-Sáenz Jose Ángel , Cejalvo Juan Miguel , Herranz Jesus , Torres Roberto , Haba-Rodriguez Juan de la , Ayala Francisco , Gómez Henry , Rojo Federico , Nielsen Torsten O. , Martin Miguel
Published: April 2023

Supplementary Data S1 shows exploratory analysis for the predictive capacity of the continuous expression of additional genes and metagenes included in the codeset.
Supplementary Data S2 shows exploratory analysis for the prognostic capacity of the continuous expression of the selected genes and metagenes
Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Authors: Kebir Sied , Ullrich Vivien , Berger Pia , Dobersalske Celia , Langer Sarah , Rauschenbach Laurèl , Trageser Daniel , Till Andreas , Lorbeer Franziska K. , Wieland Anja , Wilhelm-Buchstab Timo , Ahmad Ashar , Fröhlich Holger , Cima Igor , Prasad Shruthi , Matschke Johann , Jendrossek Verena , Remke Marc , Grüner Barbara M. , Roesch Alexander , Siveke Jens T. , Herold-Mende Christel , Blau Tobias , Keyvani Kathy , van Landeghem Frank K.H. , Pietsch Torsten , Felsberg Jörg , Reifenberger Guido , Weller Michael , Sure Ulrich , Brüstle Oliver , Simon Matthias , Glas Martin , Scheffler Björn
Published: April 2023

Supplementary Table S1. Discovery cohort of vital cells; Supplementary Table S2. Validation cohort/FFPE tissue samples; Supplementary Table S3. Differentially regulated genes; Supplementary Table S4. Selected gene variants compared between the paired treatment-naive vs. relapse cell samples.
Supplementary Data from Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)
Authors: Babiker Hani , Borazanci Erkut , Subbiah Vivek , Agarwala Sanjiv , Algazi Alain , Schachter Jacob , Lotem Michael , Maurice-Dror Corinne , Hendler Daniel , Rahimian Shah , Minderman Hans , Haymaker Cara , Mahadevan Daruka , Bernatchez Chantale , Murthy Ravi , Hultsch Rolf , Kaplan Nadia , Woodhead Gregory , Hennemeyer Charles , Chunduru Srinivas , Anderson Peter M. , Diab Adi , Puzanov Igor
Published: April 2023

Supplementary Data from Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)
Supplementary Data from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
Authors: Torrens Laura , Puigvehí Marc , Torres-Martín Miguel , Wang Huan , Maeda Miho , Haber Philipp K. , Leonel Thais , García-López Mireia , Esteban-Fabró Roger , Leow Wei Qiang , Montironi Carla , Torrecilla Sara , Varadarajan Ajay Ramakrishnan , Taik Patricia , Campreciós Genís , Enkhbold Chinbold , Taivanbaatar Erdenebileg , Yerbolat Amankyeldi , Villanueva Augusto , Pérez-del-Pulgar Sofía , Thung Swan , Chinburen Jigjidsuren , Letouzé Eric , Zucman-Rossi Jessica , Uzilov Andrew , Neely Jaclyn , Forns Xavier , Roayaie Sasan , Sia Daniela , Llovet Josep M.
Published: April 2023

Supplementary Data from Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents
Supplementary Table 5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Authors: Hahn Andrew W. , Menk Ashley V. , Rivadeneira Dayana B. , Augustin Ryan C. , Xu Mingchu , Li Jun , Wu Xiaogang , Mishra Aditya K. , Gide Tuba N. , Quek Camelia , Zang Yan , Spencer Christine N. , Menzies Alexander M. , Daniel Carrie R. , Hudgens Courtney W. , Nowicki Theodore , Haydu Lauren E. , Khan M.A. Wadud , Gopalakrishnan Vancheswaran , Burton Elizabeth M. , Malke Jared , Simon Julie M. , Bernatchez Chantale , Putluri Nagireddy , Woodman Scott E. , Vashisht Gopal Y.N. , Guerrieri Renato , Fischer Grant M. , Wang Jian , Wani Khalida M. , Thompson John F. , Lee Jeffrey E. , Hwu Patrick , Ajami Nadim , Gershenwald Jeffrey E. , Long Georgina V. , Scolyer Richard A. , Tetzlaff Michael T. , Lazar Alexander J. , Schadendorf Dirk , Wargo Jennifer A. , Kirkwood John M. , DeBerardinis Ralph J. , Liang Han , Futreal Andrew , Zhang Jianhua , Wilmott James S. , Peng Weiyi , Davies Michael A. , Delgoffe Greg M. , Najjar Yana G. , McQuade Jennifer L.
Published: April 2023

RNASeq data for the MDA cohort (n=61) with associated clinical info.
Supplementary Figure S6 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Authors: Hahn Andrew W. , Menk Ashley V. , Rivadeneira Dayana B. , Augustin Ryan C. , Xu Mingchu , Li Jun , Wu Xiaogang , Mishra Aditya K. , Gide Tuba N. , Quek Camelia , Zang Yan , Spencer Christine N. , Menzies Alexander M. , Daniel Carrie R. , Hudgens Courtney W. , Nowicki Theodore , Haydu Lauren E. , Khan M.A. Wadud , Gopalakrishnan Vancheswaran , Burton Elizabeth M. , Malke Jared , Simon Julie M. , Bernatchez Chantale , Putluri Nagireddy , Woodman Scott E. , Vashisht Gopal Y.N. , Guerrieri Renato , Fischer Grant M. , Wang Jian , Wani Khalida M. , Thompson John F. , Lee Jeffrey E. , Hwu Patrick , Ajami Nadim , Gershenwald Jeffrey E. , Long Georgina V. , Scolyer Richard A. , Tetzlaff Michael T. , Lazar Alexander J. , Schadendorf Dirk , Wargo Jennifer A. , Kirkwood John M. , DeBerardinis Ralph J. , Liang Han , Futreal Andrew , Zhang Jianhua , Wilmott James S. , Peng Weiyi , Davies Michael A. , Delgoffe Greg M. , Najjar Yana G. , McQuade Jennifer L.
Published: April 2023

Direct metabolite measurements from a subset of The Cancer Genome Atlas (TCGA) cohort.
Comparison of additional tricarboxylic acid cycle metabolites measured by liquid chromatography/mass spectrometry between metastatic melanoma tumors from overweight/obese (OW/OB) patients by body mass index (BMI) verse normal (NL) BMI from The Cancer Genome Atlas (TCGA). Lines represent mean +/- SEM; each dot represents a single tumor.
Supplementary Figure S5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
Authors: Hahn Andrew W. , Menk Ashley V. , Rivadeneira Dayana B. , Augustin Ryan C. , Xu Mingchu , Li Jun , Wu Xiaogang , Mishra Aditya K. , Gide Tuba N. , Quek Camelia , Zang Yan , Spencer Christine N. , Menzies Alexander M. , Daniel Carrie R. , Hudgens Courtney W. , Nowicki Theodore , Haydu Lauren E. , Khan M.A. Wadud , Gopalakrishnan Vancheswaran , Burton Elizabeth M. , Malke Jared , Simon Julie M. , Bernatchez Chantale , Putluri Nagireddy , Woodman Scott E. , Vashisht Gopal Y.N. , Guerrieri Renato , Fischer Grant M. , Wang Jian , Wani Khalida M. , Thompson John F. , Lee Jeffrey E. , Hwu Patrick , Ajami Nadim , Gershenwald Jeffrey E. , Long Georgina V. , Scolyer Richard A. , Tetzlaff Michael T. , Lazar Alexander J. , Schadendorf Dirk , Wargo Jennifer A. , Kirkwood John M. , DeBerardinis Ralph J. , Liang Han , Futreal Andrew , Zhang Jianhua , Wilmott James S. , Peng Weiyi , Davies Michael A. , Delgoffe Greg M. , Najjar Yana G. , McQuade Jennifer L.
Published: April 2023

Immune cell analysis by BMI and sex.
A. Immunohistochemistry (IHC) analysis of the MDA cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor.
B. IHC analysis of the Gide cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor.
Supplementary Figure S3 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation
Authors: Serra-Camprubí Queralt , Verdaguer Helena , Oliveros Winona , Lupión-Garcia Núria , Llop-Guevara Alba , Molina Cristina , Vila-Casadesús Maria , Turpin Anthony , Neuzillet Cindy , Frigola Joan , Querol Jessica , Yáñez-Bartolomé Mariana , Castet Florian , Fabregat-Franco Carles , Escudero-Iriarte Carmen , Escorihuela Marta , Arenas Enrique J. , Bernadó-Morales Cristina , Haro Noemí , Giles Francis J. , Pozo Óscar J. , Miquel Josep M. , Nuciforo Paolo G. , Vivancos Ana , Melé Marta , Serra Violeta , Arribas Joaquín , Tabernero Josep , Peiró Sandra , Macarulla Teresa , Tian Tian V.
Published: April 2023

Genomic rearrangements resulting in FGFR2 fusions. (A) Genomic rearrangements resulting in FGFR2 fusion identified in CCA_PDX and the corresponding biopsy samples. Fusion partner genes, their accession number, breakpoints, and predicted chimeric protein products are indicated.
Supplementary Figure from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Authors: Banerjee Susana , Michalarea Vasiliki , Ang Joo Ern , Ingles Garces Alvaro , Biondo Andrea , Funingana Ionut-Gabriel , Little Martin , Ruddle Ruth , Raynaud Florence , Riisnaes Ruth , Gurel Bora , Chua Sue , Tunariu Nina , Porter Joanna C. , Prout Toby , Parmar Mona , Zachariou Anna , Turner Alison , Jenkins Ben , McIntosh Stuart , Ainscow Ed , Minchom Anna , Lopez Juanita , de Bono Johann , Jones Robert , Hall Emma , Cook Natalie , Basu Bristi , Banerji Udai
Published: April 2023

Supplementary Figure from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Supplementary Figure S3 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Authors: Verhoeff Sarah R. , Oosting Sjoukje F. , Elias Sjoerd G. , van Es Suzanne C. , Gerritse Sophie L. , Angus Lindsay , Heskamp Sandra , Desar Ingrid M.E. , Menke-van der Houven van Oordt C. Willemien , van der Veldt Astrid A.M. , Arens Anne I.J. , Brouwers Adrienne H. , Eisses Bertha , Mulders Peter F.A. , Hoekstra Otto S. , Zwezerijnen Gerben J.C. , van der Graaf Winette T.A. , Aarntzen Erik H.J.G. , Oyen Wim J.G. , van Herpen Carla M.L.
Published: April 2023

Flow-chart patients according to RECIST-defined PD.
*All patients had clinical disease progression; no CT-imaging was performed before initiation of systemic treatment
** In total 7 patients choose best supportive care. Three other patients underwent radiotherapy or surgery of all target lesions.
Supplement LASSO from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
Authors: Verhoeff Sarah R. , Oosting Sjoukje F. , Elias Sjoerd G. , van Es Suzanne C. , Gerritse Sophie L. , Angus Lindsay , Heskamp Sandra , Desar Ingrid M.E. , Menke-van der Houven van Oordt C. Willemien , van der Veldt Astrid A.M. , Arens Anne I.J. , Brouwers Adrienne H. , Eisses Bertha , Mulders Peter F.A. , Hoekstra Otto S. , Zwezerijnen Gerben J.C. , van der Graaf Winette T.A. , Aarntzen Erik H.J.G. , Oyen Wim J.G. , van Herpen Carla M.L.
Published: April 2023

Lasso model
Supplementary Figure from A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
Authors: Taniguchi Yuri , Shimokawa Tsuneo , Takiguchi Yuichi , Misumi Toshihiro , Nakamura Yukiko , Kawashima Yosuke , Furuya Naoki , Shiraishi Yoshimasa , Harada Toshiyuki , Tanaka Hisashi , Miura Satoru , Uchiyama Ayumi , Nakahara Yoshiro , Tokito Takaaki , Naoki Katsuhiko , Bessho Akihiro , Goto Yasuhiro , Seike Masahiro , Okamoto Hiroaki
Published: April 2023

Supplementary Figure from A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
Supplementary Data 3 from The Mutational Landscape of Cancer's Vulnerability to Ionizing Radiation
Authors: Gopal Priyanka , Yard Brian D. , Petty Aaron , Lal Jessica C. , Bera Titas K. , Hoang Trung Q. , Buhimschi Alexandru D. , Abazeed Mohamed E.
Published: April 2023

Supplementary Data 3: Annotation of Databases used to classify variants
Supplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Authors: Giraldo Nicolas A. , Drill Esther , Satravada Baby A. , Dika Imane El , Brannon A. Rose , Dermawan Josephine , Mohanty Abhinita , Ozcan Kerem , Chakravarty Debyani , Benayed Ryma , Vakiani Efsevia , Abou-Alfa Ghassan K. , Kundra Ritika , Schultz Nikolaus , Li Bob T. , Berger Michael F. , Harding James J. , Ladanyi Marc , O'Reilly Eileen M. , Jarnagin William , Vanderbilt Chad , Basturk Olca , Arcila Maria E.
Published: April 2023

Table S1. Sample list (cBioPortal identifiers, ‘DMP_SAMPLE_ID’). Only the primary tumor (if available) or the earliest collected metastasis are included (n=233)
Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Authors: Oh Seung Yeon , Lee You Won , Lee Eun Ji , Kim Jae Hwan , Park YoungJoon , Heo Seong Gu , Yu Mi Ra , Hong Min Hee , DaSilva John , Daly Christopher , Cho Byoung Chul , Lim Sun Min , Yun Mi Ran
Published: April 2023

Information of ATCC cell lines
Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Authors: Vaishampayan Ulka N. , Thakur Archana , Chen Wei , Deol Abhinav , Patel Meera , Dobson Kimberlee , Dickow Brenda , Schalk Dana , Schienschang Amy , Whitaker Sarah , Polend Amanda , Fontana Joseph A. , Heath Elisabeth I. , Lum Lawrence G.
Published: April 2023

Shows the persistence of anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) in the peripheral blood of two out of four patients.
Supplementary Table 5 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
Authors: Mierzwa Michelle L. , Aryal Madhava , Lee Choonik , Schipper Matthew , VanTil Monica , Morales Krystal , Swiecicki Paul L. , Casper Keith A. , Malloy Kelly M. , Spector Matthew E. , Shuman Andrew G. , Chinn Steven B. , Prince Mark E.P. , Stucken Chaz L. , Rosko Andrew J. , Lawrence Theodore S. , Brenner J. Chad , Rosen Benjamin , Schonewolf Caitlin A. , Shah Jennifer , Eisbruch Avraham , Worden Francis P. , Cao Yue
Published: April 2023

Odds ratios (OR) and p values for multi-variable models for acute and late toxicity outcomes including covariates of p16+ OPSCC vs LAHNSCC, primary tumor volume (GTVp) and RT boost volume treated.
Supplementary Table from A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses
Authors: Irajizad Ehsan , Han Chae Y. , Celestino Joseph , Wu Ranran , Murage Eunice , Spencer Rachelle , Dennison Jennifer B. , Vykoukal Jody , Long James P. , Do Kim Anh , Drescher Charles , Lu Karen , Lu Zhen , Bast Robert C. , Hanash Sam , Fahrmann Johannes F.
Published: April 2023

Supplementary Table from A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses
Supplementary Data from A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses
Authors: Irajizad Ehsan , Han Chae Y. , Celestino Joseph , Wu Ranran , Murage Eunice , Spencer Rachelle , Dennison Jennifer B. , Vykoukal Jody , Long James P. , Do Kim Anh , Drescher Charles , Lu Karen , Lu Zhen , Bast Robert C. , Hanash Sam , Fahrmann Johannes F.
Published: April 2023

Supplementary Data from A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses
Supplementary Data from Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma
Authors: Tang Xinyi , Yang Zhi-Zhang , Kim Hyo Jin , Anagnostou Theodora , Yu Yue , Wu Xiaosheng , Chen Jun , Krull Jordan E. , Wenzl Kerstin , Mondello Patrizia , Bhardwaj Vaishali , Wang Junwen , Novak Anne J. , Ansell Stephen M.
Published: April 2023

Supplementary Data from Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma
Figure S1 from NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects
Authors: Belhadj Sami , Khurram Aliya , Bandlamudi Chaitanya , Palou-Márquez Guillermo , Ravichandran Vignesh , Steinsnyder Zoe , Wildman Temima , Catchings Amanda , Kemel Yelena , Mukherjee Semanti , Fesko Benjamin , Arora Kanika , Mehine Miika , Dandiker Sita , Izhar Aalin , Petrini John , Domchek Susan , Nathanson Katherine L. , Brower Jamie , Couch Fergus , Stadler Zsofia , Robson Mark , Walsh Michael , Vijai Joseph , Berger Michael , Supek Fran , Karam Rachid , Topka Sabine , Offit Kenneth
Published: April 2023

Supplementary Figure S1. Germline and somatic data from The Cancer Genome Atlas (TCGA) project, representing 10,268 cancer patients with whole exome sequencing data.
Supplementary Data from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Authors: Chi Kim N. , Barnicle Alan , Sibilla Caroline , Lai Zhongwu , Corcoran Claire , Barrett J. Carl , Adelman Carrie A. , Qiu Ping , Easter Ashley , Dearden Simon , Oxnard Geoffrey R. , Agarwal Neeraj , Azad Arun , de Bono Johann , Mateo Joaquin , Olmos David , Thiery-Vuillemin Antoine , Harrington Elizabeth A.
Published: April 2023

Supplementary Data from Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Supplementary Data from Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
Authors: Bolton Kelly L. , Chen Denise , Corona de la Fuente Rosario , Fu Zhuxuan , Murali Rajmohan , Köbel Martin , Tazi Yanis , Cunningham Julie M. , Chan Irenaeus C.C. , Wiley Brian J. , Moukarzel Lea A. , Winham Stacey J. , Armasu Sebastian M. , Lester Jenny , Elishaev Esther , Laslavic Angela , Kennedy Catherine J. , Piskorz Anna , Sekowska Magdalena , Brand Alison H. , Chiew Yoke-Eng , Pharoah Paul , Elias Kevin M. , Drapkin Ronny , Churchman Michael , Gourley Charlie , DeFazio Anna , Karlan Beth , Brenton James D. , Weigelt Britta , Anglesio Michael S. , Huntsman David , Gayther Simon , Konner Jason , Modugno Francesmary , Lawrenson Kate , Goode Ellen L. , Papaemmanuil Elli
Published: April 2023

Supplementary Data from Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
Supplementary Table 3 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
Authors: Haertle Larissa , Barrio Santiago , Munawar Umair , Han Seungbin , Zhou Xiang , Simicek Michal , Vogt Cornelia , Truger Marietta , Fernandez Rafael Alonso , Steinhardt Maximilian , Weingart Julia , Snaurova Renata , Nerreter Silvia , Teufel Eva , Garitano-Trojaola Andoni , Da Viá Matteo , Ruiz-Heredia Yanira , Rosenwald Andreas , Bolli Niccolò , Hajek Roman , Raab Peter , Raab Marc S. , Weinhold Niels , Haferlach Claudia , Haaf Thomas , Martinez-Lopez Joaquin , Einsele Hermann , Rasche Leo , Kortüm K. Martin
Published: April 2023

Primers used for luciferase reporter assay.
Supplementary Figure 2 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
Authors: Haertle Larissa , Barrio Santiago , Munawar Umair , Han Seungbin , Zhou Xiang , Simicek Michal , Vogt Cornelia , Truger Marietta , Fernandez Rafael Alonso , Steinhardt Maximilian , Weingart Julia , Snaurova Renata , Nerreter Silvia , Teufel Eva , Garitano-Trojaola Andoni , Da Viá Matteo , Ruiz-Heredia Yanira , Rosenwald Andreas , Bolli Niccolò , Hajek Roman , Raab Peter , Raab Marc S. , Weinhold Niels , Haferlach Claudia , Haaf Thomas , Martinez-Lopez Joaquin , Einsele Hermann , Rasche Leo , Kortüm K. Martin
Published: April 2023

Quality check of DBS assays with artificially methylated standard DNAs.
DNA standards of 0%, 25%, 50%, 75% and 100% methylation were sequenced with the PSMB5, PSMC2, PSMC5, PSMC6, PSMD1 and PSMD5 DBS assays to confirm assay sensitivity. Results for all investigated DBS amplicons correlated well with the expected curves (P < 0.001) (A). The sequencing depths of the PSMD5 DBS assay was 10-3 (B).
Supplementary Figure from Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors
Authors: Solomon James P. , Yang Soo-Ryum , Choudhury Noura J. , Ptashkin Ryan N. , Eslamdoost Nasrin , Falcon Christina J. , Martin Axel , Plodkowski Andrew , Wilhelm Clare , Shen Ronglai , Ladanyi Marc , Berger Michael , Zhang Yanming , Drilon Alexander , Arcila Maria E.
Published: April 2023

Supplementary Figure from Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors
Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Authors: Chen Tom Wei-Wu , Hsu Chia-Lang , Hong Ruey-Long , Lee Jen-Chieh , Chang Koping , Yu Chih-Wei , Chen San-Chi , Guo Jhe-Cyuan , Chen Mei-Lu , Hsu Meng-Chi , Kung Ting-Fang , Cheng Ann-Lii , Yen Chueh-Chuan
Published: April 2023

Supplementary Table 1a. Differentially expressed genes between Post-treatment vs Pre-treatment; Supplementary Table 1b. Differentially expressed genes between Responders vs Nonresponders; Supplementary Table 1c. Differentially expressed genes between PFS longer than 6 months vs PFS shorter than 6 months.
Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Authors: Chen Tom Wei-Wu , Hsu Chia-Lang , Hong Ruey-Long , Lee Jen-Chieh , Chang Koping , Yu Chih-Wei , Chen San-Chi , Guo Jhe-Cyuan , Chen Mei-Lu , Hsu Meng-Chi , Kung Ting-Fang , Cheng Ann-Lii , Yen Chueh-Chuan
Published: April 2023

CONSORT diagram
Supplementary Table S3 from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Authors: O'Connell Casey L. , Baer Maria R. , Ørskov Andreas Due , Saini Sunil Kumar , Duong Vu H. , Kropf Patricia , Hansen Jakob Werner , Tsao-Wei Denice , Jang Hyo Sik , Emadi Ashkan , Holmberg-Thyden Staffan , Cowland Jack , Brinker Brett T. , Horwood Kristin , Burgos Ryan , Hostetter Galen , Youngblood Benjamin A. , Hadrup Sine Reker , Issa Jean-Pierre , Jones Peter , Baylin Stephen B. , Siddiqi Imran , Grønbaek Kirsten
Published: April 2023

List of Patients Who Experienced Immune-related Adverse Events AEs.
Supplementary Table S2 from Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance
Authors: Carney Stephen V. , Banerjee Kaushik , Mujeeb Anzar , Zhu Brandon , Haase Santiago , Varela Maria L. , Kadiyala Padma , Tronrud Claire E. , Zhu Ziwen , Mukherji Devarshi , Gorla Preethi , Sun Yilun , Tagett Rebecca , Núñez Felipe J. , Luo Maowu , Luo Weibo , Ljungman Mats , Liu Yayuan , Xia Ziyun , Schwendeman Anna , Qin Tingting , Sartor Maureen A. , Costello Joseph F. , Cahill Daniel P. , Lowenstein Pedro R. , Castro Maria G.
Published: April 2023

Table S2. Liquid Chromatography and Mass Spectrometry Measurement of 2-hydroxyglutarate in the Conditioned Media of mIDH1 GCCs untreated, treated with vehicle (DMSO), or mIDH1 inhibitor (AGI-5198 or DS1001b)
Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
Authors: Robert Caroline , Lebbé Céleste , Lesimple Thierry , Lundström Eija , Nicolas Valérie , Gavillet Bruno , Crompton Philippa , Baroudjian Barouyr , Routier Emilie , Lejeune Ferdy J.
Published: April 2023

Washout, response to protocol therapy, AEs
Supplementary Data S1 from NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Authors: Janssens Katleen , Vanhoutte Greetje , Lybaert Willem , Demey Wim , Decaestecker Jochen , Hendrickx Koen , Rezaei Kalantari Hassan , Zwaenepoel Karen , Pauwels Patrick , Fransen Erik , Op de Beeck Ken , Van Camp Guy , Rolfo Christian , Peeters Marc
Published: April 2023

Supplementary data on the comparison of anti-EGFR therapy to anti-VEGF therapy.
Supplementary Figure 6 from Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
Authors: Rugo Hope S. , Raskina Kira , Schrock Alexa B. , Madison Russell W. , Graf Ryon P. , Sokol Ethan S. , Sivakumar Smruthy , Lee Jessica K. , Fisher Virginia , Oxnard Geoffrey R. , Tukachinsky Hanna
Published: April 2023

Supplementary Figure 6. OTHERm variants show a range of subclonality andindependent oncogenicity
Supplementary Figure 4 from Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
Authors: Rugo Hope S. , Raskina Kira , Schrock Alexa B. , Madison Russell W. , Graf Ryon P. , Sokol Ethan S. , Sivakumar Smruthy , Lee Jessica K. , Fisher Virginia , Oxnard Geoffrey R. , Tukachinsky Hanna
Published: April 2023

Supplementary Figure 4. Impact of ctDNA fraction on sensitivity of detection of PIK3CAmutations.
Supplementary Figure 3 from Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
Authors: Rugo Hope S. , Raskina Kira , Schrock Alexa B. , Madison Russell W. , Graf Ryon P. , Sokol Ethan S. , Sivakumar Smruthy , Lee Jessica K. , Fisher Virginia , Oxnard Geoffrey R. , Tukachinsky Hanna
Published: April 2023

Supplementary Figure 3. PIK3CA variants detected in paired tissue and liquid samples.
Figure S5 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Authors: Debie Yana , Van Audenaerde Jonas R.M. , Vandamme Timon , Croes Lieselot , Teuwen Laure-Anne , Verbruggen Lise , Vanhoutte Greetje , Marcq Elly , Verheggen Lisa , Le Blon Debbie , Peeters Bart , Goossens Maria E. , Pannus Pieter , Ariën Kevin K. , Anguille Sébastien , Janssens Annelies , Prenen Hans , Smits Evelien L.J. , Vulsteke Christof , Lion Eva , Peeters Marc , van Dam Peter A.
Published: April 2023

Supplementary Figure 5: Spike-specific CD8+ T cell responses post homologous or heterologous booster vaccination in subcohorts.
Supplementary Table S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Authors: Visvanathan Kala , Cope Leslie , Fackler Mary Jo , Considine Michael , Sokoll Lori , Carey Lisa A. , Forero-Torres Andres , Ingle James N. , Lin Nancy U. , Nanda Rita , Storniolo Anna Maria , Tulac Suzana , Venkatesan Neesha , Wu Natalie C. , Marla Sudhakar , Campbell Scott , Bates Michael , Umbricht Christopher B. , Wolff Antonio C. , Sukumar Saraswati
Published: April 2023

Association between week 4 CM and disease status at first restaging after adjusting for CTC
Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Authors: Visvanathan Kala , Cope Leslie , Fackler Mary Jo , Considine Michael , Sokoll Lori , Carey Lisa A. , Forero-Torres Andres , Ingle James N. , Lin Nancy U. , Nanda Rita , Storniolo Anna Maria , Tulac Suzana , Venkatesan Neesha , Wu Natalie C. , Marla Sudhakar , Campbell Scott , Bates Michael , Umbricht Christopher B. , Wolff Antonio C. , Sukumar Saraswati
Published: April 2023

Supplementary Figure 2 displays the relationship between the week 8 CM level and the change in CM level (Week 8 – baseline). Figure S4B and C use box plots to display the relationship between disease status at first restaging and week 8 CM level or change in CM level (Week 8 – baseline).
Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Authors: Chen Evan C. , Gandler Helen , Tošić Isidora , Fell Geoffrey G. , Fiore Ashlee , Pozdnyakova Olga , DeAngelo Daniel J. , Galinsky Ilene , Luskin Marlise R. , Wadleigh Martha , Winer Eric S. , Leonard Rebecca , O'Day Kelsey , de Jonge Adrienne , Neuberg Donna , Look A. Thomas , Stone Richard M. , Frank David A. , Garcia Jacqueline S.
Published: April 2023

Merestinib and LY2874455 inhibit MET-activated signal transduction. A, AML cell lines treated with merestinib and LY2874455 in vitro for 1 hour exhibited decreased levels of pSTAT3 and pSTAT5 by phospho-flow cytometry. Standard errors are shown for KG1a (n=3) and HEL (n=2) cell lines. Representative flow cytometry histograms are shown in B. Reverse transcription-PCR showing decreased expression of CISH, a downstream target of STAT5, is displayed in C. Abbreviations: U = unstained; FGFRi = the FGFR inhibitor LY2874455.
Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Authors: Chen Evan C. , Gandler Helen , Tošić Isidora , Fell Geoffrey G. , Fiore Ashlee , Pozdnyakova Olga , DeAngelo Daniel J. , Galinsky Ilene , Luskin Marlise R. , Wadleigh Martha , Winer Eric S. , Leonard Rebecca , O'Day Kelsey , de Jonge Adrienne , Neuberg Donna , Look A. Thomas , Stone Richard M. , Frank David A. , Garcia Jacqueline S.
Published: April 2023

Study design.
Supplementary Figure S6 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
Authors: Sivakumar Smruthy , Jin Dexter X. , Rathod Ruchita , Ross Jeffrey , Cantley Lewis C. , Scaltriti Maurizio , Chen Jessica W. , Hutchinson Katherine E. , Wilson Timothy R. , Sokol Ethan S. , Vasan Neil
Published: April 2023

Prevalence of different PIK3CA mutation subgroups based on tumor mutational burden (TMB) and APOBEC status.
Supplementary Figure S4 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
Authors: Sivakumar Smruthy , Jin Dexter X. , Rathod Ruchita , Ross Jeffrey , Cantley Lewis C. , Scaltriti Maurizio , Chen Jessica W. , Hutchinson Katherine E. , Wilson Timothy R. , Sokol Ethan S. , Vasan Neil
Published: April 2023

Mutual exclusivity of multi-PIK3CA mutations with other gene alterations in the PI3K pathway.
Table S2 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Authors: Pietrantonio Filippo , Manca Paolo , Bellomo Sara Erika , Corso Simona , Raimondi Alessandra , Berrino Enrico , Morano Federica , Migliore Cristina , Niger Monica , Castagnoli Lorenzo , Pupa Serenella Maria , Marchiò Caterina , Di Bartolomeo Maria , Restuccia Eleonora , Lambertini Chiara , Tabernero Josep , Giordano Silvia
Published: April 2023

PFS and OS in the subgroups identified by the combined assessment of HER2 CNV and HER2 IHC or the combined assessment of HER2 CNV and AMNESIA panel
Table S1 from HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
Authors: Pietrantonio Filippo , Manca Paolo , Bellomo Sara Erika , Corso Simona , Raimondi Alessandra , Berrino Enrico , Morano Federica , Migliore Cristina , Niger Monica , Castagnoli Lorenzo , Pupa Serenella Maria , Marchiò Caterina , Di Bartolomeo Maria , Restuccia Eleonora , Lambertini Chiara , Tabernero Josep , Giordano Silvia
Published: April 2023

Univariate analysis for each specific genomic alteration encompassed in the AMNESIA panel in terms of both PFS and OS. P-values were adjusted using the FDR method
Supplementary Data S1 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
Authors: van 't Erve Iris , Medina Jamie E. , Leal Alessandro , Papp Eniko , Phallen Jillian , Adleff Vilmos , Chiao Elaine Jiayuee , Arun Adith S. , Bolhuis Karen , Simmons John K. , Karandikar Aanavi , Valkenburg Kenneth C. , Sausen Mark , Angiuoli Samuel V. , Scharpf Robert B. , Punt Cornelis J.A. , Meijer Gerrit A. , Velculescu Victor E. , Fijneman Remond J.A.
Published: April 2023

Supplementary Data 1 shows an overview of ctDNA dynamics, treatments, and radiological response measurements per patient.
Figure S6 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Authors: Von Roemeling Christina A. , Doonan Bently P. , Klippel Kelena , Schultz Daniel , Hoang-Minh Lan , Trivedi Vrunda , Li Chenglong , Russell Rylynn A. , Kanumuri Raju S. , Sharma Abhisheak , Tun Han W. , Mitchell Duane A.
Published: April 2023

Supplemental Figure 6. CA-4948 inhibition of MAPK and NF-κB signaling in MBM.